Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. / Holst, Jens Juul; Deacon, Carolyn F.
In: Current Opinion in Pharmacology, Vol. 4, No. 6, 2004, p. 589-96.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.
AU - Holst, Jens Juul
AU - Deacon, Carolyn F
N1 - Keywords: Animals; Antigens, CD26; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Great Britain; Humans; Peptide Fragments; Protease Inhibitors; Protein Precursors
PY - 2004
Y1 - 2004
N2 - Proof-of-concept for the efficacy of a glucagon-like peptide 1 (GLP-1)-based therapy of patients with type 2 diabetes was provided in 2002 by means of prolonged continuous subcutaneous infusion of native GLP-1. Since then, several long-acting analogues of GLP-1, as well as inhibitors of dipeptidyl peptidase IV, the enzyme that rapidly inactivates endogenous GLP-1, have demonstrated efficacy in long term clinical trials.
AB - Proof-of-concept for the efficacy of a glucagon-like peptide 1 (GLP-1)-based therapy of patients with type 2 diabetes was provided in 2002 by means of prolonged continuous subcutaneous infusion of native GLP-1. Since then, several long-acting analogues of GLP-1, as well as inhibitors of dipeptidyl peptidase IV, the enzyme that rapidly inactivates endogenous GLP-1, have demonstrated efficacy in long term clinical trials.
U2 - 10.1016/j.coph.2004.08.005
DO - 10.1016/j.coph.2004.08.005
M3 - Journal article
C2 - 15525549
VL - 4
SP - 589
EP - 596
JO - Current Opinion in Pharmacology
JF - Current Opinion in Pharmacology
SN - 1471-4892
IS - 6
ER -
ID: 8417324